

Tze-Fan Chao, M.D., Ph.D. Taipei, Taiwan

Electrophysiologist, Division of Cardiology, Taipei Veterans General Hospital, Taipei, Taiwan

Associate Professor, National Yang Ming Chiao Tung University, Taipei, Taiwan

Chair of the APHRS practical guideline subcommittee

ESC annual congress – Abstract Grader (2018-2022)

Section Editor of “Thrombosis and Haemostasis”

Dr. Chao's research interests are in the areas of atrial fibrillation, including epidemiology, stroke risk stratification and oral anticoagulants for stroke prevention. He has published a series of original articles as first, co-first or corresponding author in SCI journals including *Circulation*, *JACC*, *European Heart Journal*, and etc.

Dr. Chao is the chair of the writing committee for the 2021 atrial fibrillation stroke prevention guidelines of the Asia Pacific Heart Rhythm Society (APHRS). Currently, he is the chair of the APHRS practical guideline subcommittee and section editor of “Thrombosis and Haemostasis”.

Important publications in top journals (First or corresponding author only)

1. **Chao TF**, Chen SA. CHADS₂ and CHA₂DS₂-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation. *J Am Coll Cardiol* 2011;**58**:2380-85.
2. **Chao TF**, Lip GY, Chen SA. Using the CHA₂DS₂-VASc Score for Refining Stroke Risk Stratification in 'Low-Risk' Asian Patients With Atrial Fibrillation. *J Am Coll Cardiol* 2014;**64**:1658-1665.
3. **Chao TF**, Lip GY, Chen SA. Should Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA₂DS₂-VASc Score (Beyond Sex) Receive Oral Anticoagulation? *J Am Coll Cardiol* 2015;**65**:635-642.
4. **Chao TF**, Lip GY, Chen SA. Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation: A Nationwide Cohort Study From Taiwan. *J Am Coll Cardiol* 2015;**66**:1339-1347.
5. **Chao TF**, Chiang CE, Chen SA. Rate-Control Treatment and Mortality in Atrial Fibrillation. *Circulation* 2015;**132**:1604-1612.
6. **Chao TF**, et al. The Use of Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Patients with History of Intra-Cranial Hemorrhage. *Circulation* 2016;**133**:1540-1547.
7. **Chao TF**, Lip GYH, Chen SA. Relationship of Aging and Incident Comorbidities to Stroke Risk in Patients With Atrial Fibrillation. *J Am Coll Cardiol* 2018;**71**:122-132.
8. **Chao TF**, Lip GYH, Chen SA. Oral Anticoagulation in Very Elderly Patients with Atrial Fibrillation - A Nationwide Cohort Study. *Circulation* 2018;**138**:37-47.
9. **Chao TF**, Lip GYH, Chen SA. Evolving Changes of the Use of Oral Anticoagulants and Outcomes in Patients With Newly Diagnosed Atrial Fibrillation in Taiwan. *Circulation* 2018;**138**:1485-1487.
10. **Chao TF**, Chen SA, Ruff CT, Hamershock RA, Mercuri MF, Antman EM, Braunwald E, Giugliano RP. Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. *Eur Heart J* 2019;**40**:1518-1527.
11. **Chao TF**, Lip GYH, Chen SA. Reassessment of Risk for Stroke During Follow-up of Patients With Atrial Fibrillation. *Ann Intern Med* 2019;**170**:663-664.
12. **Chao TF**, Lip GYH, Chen SA. Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities. *Eur Heart J* 2019;**40**:1504-1514.
13. Chan YH, **Chao TF**, Kuo CT, Lip GYH, Chen SA. Impacts of Different Renal Function Estimation Formulas on Dosing of DOACs and Clinical Outcomes. *J Am Coll Cardiol* 2020;**76**:1808-1810. (corresponding author)